GlassScriptPhysician profile
Mehul D Shah
NPI 1447577028
$8,354.90
in general payments reported to CMS, 2019-2025
25 companies · $75.82 in 2025
The $75.82 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $867 · 2021: $771 · 2022: $4,956 · 2023: $280 · 2024: $278 · 2025: $75.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $4,022.97 | 2022-2024 | Sprint Pns System |
| Nevro Corp. | $1,307.73 | 2019-2022 | |
| Boston Scientific Corporation | $872.56 | 2019-2023 | |
| Abbott Laboratories | $514.73 | 2019-2022 | |
| Stryker Corporation | $333.79 | 2022-2023 | Avs Anchor-L |
| Vertos Medical, INC. | $204.88 | 2020-2022 | |
| Medtronic, INC. | $198.84 | 2021-2022 | |
| Biotronik Nro, INC. | $143.86 | 2024 | Prospera |
| Djo, LLC | $88.15 | 2024 | Cmf |
| Scilex Pharmaceuticals INC. | $81.92 | 2021-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $74.95 | 2019-2020 | |
| Nalu Medical, INC. | $74.45 | 2021-2023 | Nalu Neurostimulation System |
| Pfizer INC. | $67.31 | 2019-2020 | |
| Lilly USA, LLC | $55.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.22 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $47.20 | 2024-2025 | Durolane, Gelsyn-3 |
| Si-Bone, INC. | $39.84 | 2019-2022 | |
| Ossdsign USA Incorporated | $38.96 | 2025 | Ossdsign Catalyst |
| Hikma Pharmaceuticals USA | $34.84 | 2022 | |
| Medtronic USA, INC. | $24.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.23 | 2025 | Wainua |
| Amgen INC. | $14.26 | 2021 | |
| Pacira Therapeutics, INC. | $13.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.